A new UCLA Health Jonsson Comprehensive Cancer Center study suggests that the way immune cells are organized inside melanoma tumors may help researchers better understand which patients will benefit from combination immunotherapy after standard anti-PD-1 treatment stops working - and which may not.

In a National Institutes of Health (NIH)-funded study, researchers developed a cancer assessment tool that can identify high-risk patients and the tumor cells linked to that risk.